Aveni Foundation   Report issue

Foundation Phase 2
Founded: Santa Monica CA United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04378244
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Aveni Foundation

Active Ingredients

Drugs in Phase 2 Trials (1)

rexin-g (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1